MX2010000410A - Termoestabilizacion de proteinas. - Google Patents
Termoestabilizacion de proteinas.Info
- Publication number
- MX2010000410A MX2010000410A MX2010000410A MX2010000410A MX2010000410A MX 2010000410 A MX2010000410 A MX 2010000410A MX 2010000410 A MX2010000410 A MX 2010000410A MX 2010000410 A MX2010000410 A MX 2010000410A MX 2010000410 A MX2010000410 A MX 2010000410A
- Authority
- MX
- Mexico
- Prior art keywords
- cocaine
- coce
- induced condition
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01084—Cocaine esterase (3.1.1.84)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan composiciones que comprenden una esterasa de cocaína (CocE) y un compuesto que termoestabiliza la CocE. También se propriocion métodos para termoestabilizar una esterasa de cocaína. Adicionalmente se proporcionan métodos para tratar mamíferos bajo condición inducida por cocaína. Los métodos para determinar si un compuesto es un agente termoestabilizante para una proteína también se proporcionan. Los usos de las composiciones antes descritas para el tratamiento de una condición inducida por cocaína son propiorcionados adicionalmente. Además se proporciona un acido nucleótido aislado que codifica un poliopeptido CocE que tienen las sustituciones L169K y G173Q, y el poliopeptido CocE codificadop por tal acido nucleico, y composiciones farmacéuticas de los mismos. Se proporciona además el uso de tal composición para la fabricación de un medicamento para el tratamiento de una condición inducida por cocaína y para el tratamiento de una condición inducida por cocaína.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94897607P | 2007-07-10 | 2007-07-10 | |
US98766107P | 2007-11-13 | 2007-11-13 | |
PCT/US2008/069659 WO2009009669A2 (en) | 2007-07-10 | 2008-07-10 | Thermostabilization of proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010000410A true MX2010000410A (es) | 2010-05-24 |
Family
ID=40229481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010000410A MX2010000410A (es) | 2007-07-10 | 2008-07-10 | Termoestabilizacion de proteinas. |
Country Status (14)
Country | Link |
---|---|
US (3) | US8637009B2 (es) |
EP (1) | EP2170373B1 (es) |
CN (1) | CN101903038A (es) |
AU (1) | AU2008275025C1 (es) |
BR (1) | BRPI0813556A2 (es) |
CA (1) | CA2691842C (es) |
CO (1) | CO6290699A2 (es) |
DK (1) | DK2170373T3 (es) |
ES (1) | ES2510551T3 (es) |
HK (1) | HK1143309A1 (es) |
IL (1) | IL202917A (es) |
MX (1) | MX2010000410A (es) |
NZ (1) | NZ582626A (es) |
WO (1) | WO2009009669A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0714380A2 (pt) * | 2006-07-10 | 2013-03-05 | Univ Columbia | composiÇÕes anticocaÍna e tratamento |
DK2170373T3 (da) | 2007-07-10 | 2014-10-13 | Univ Columbia | Termostabilisering af proteiner |
US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
US9790233B2 (en) * | 2012-04-16 | 2017-10-17 | Case Western Reserve University | Compositions and methods of modulating 15-PGDH activity |
WO2015021187A1 (en) | 2013-08-06 | 2015-02-12 | The Trustees Of Columbia University In The City Of New York | Mutants of cocaine esterase |
EP3057973B1 (en) | 2013-10-15 | 2019-09-04 | Case Western Reserve University | Compositions comprising a 15-pgdh inhibitor for the healing of wounds |
WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
AU2018215678A1 (en) | 2017-02-06 | 2019-08-22 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
CN113481182B (zh) * | 2021-07-05 | 2022-11-15 | 杭州师范大学 | 可卡因酯酶突变体及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9115765D0 (en) * | 1991-07-22 | 1991-09-04 | Britt Adrian J | Bacterial enzyme for cocaine detection |
US5463028A (en) * | 1992-04-03 | 1995-10-31 | The Trustees Of Columbia University In The City Of New York | Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents |
US5730985A (en) * | 1994-06-13 | 1998-03-24 | Governing Council Of The University Of Toronto | Immunogens for the production of cocaine-hydrolyzing catalytic antibodies |
CA2350597A1 (en) | 1998-12-02 | 2000-06-08 | Barbara Ann Foster | Methods and compositions for restoring conformational stability of a protein of the p53 family |
US6870331B2 (en) * | 2000-05-31 | 2005-03-22 | Sarnoff Corporation | Space-saving cathode ray tube employing a non-self-converging deflection yoke |
BRPI0714380A2 (pt) * | 2006-07-10 | 2013-03-05 | Univ Columbia | composiÇÕes anticocaÍna e tratamento |
DK2170373T3 (da) | 2007-07-10 | 2014-10-13 | Univ Columbia | Termostabilisering af proteiner |
-
2008
- 2008-07-10 DK DK08781619.5T patent/DK2170373T3/da active
- 2008-07-10 US US12/667,895 patent/US8637009B2/en not_active Expired - Fee Related
- 2008-07-10 WO PCT/US2008/069659 patent/WO2009009669A2/en active Application Filing
- 2008-07-10 CA CA2691842A patent/CA2691842C/en not_active Expired - Fee Related
- 2008-07-10 ES ES08781619.5T patent/ES2510551T3/es active Active
- 2008-07-10 BR BRPI0813556-8A patent/BRPI0813556A2/pt active Search and Examination
- 2008-07-10 EP EP08781619.5A patent/EP2170373B1/en not_active Not-in-force
- 2008-07-10 MX MX2010000410A patent/MX2010000410A/es active IP Right Grant
- 2008-07-10 AU AU2008275025A patent/AU2008275025C1/en not_active Ceased
- 2008-07-10 CN CN2008801060981A patent/CN101903038A/zh active Pending
- 2008-07-10 NZ NZ582626A patent/NZ582626A/xx not_active IP Right Cessation
-
2009
- 2009-12-23 IL IL202917A patent/IL202917A/en active IP Right Grant
-
2010
- 2010-01-13 CO CO10002809A patent/CO6290699A2/es active IP Right Grant
- 2010-10-07 HK HK10109558.3A patent/HK1143309A1/xx not_active IP Right Cessation
-
2014
- 2014-01-28 US US14/166,619 patent/US9526786B2/en active Active
-
2016
- 2016-12-25 US US15/390,514 patent/US20170106056A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2170373A4 (en) | 2011-10-05 |
CA2691842A1 (en) | 2009-01-15 |
BRPI0813556A2 (pt) | 2015-06-16 |
CA2691842C (en) | 2017-05-16 |
US20110142816A1 (en) | 2011-06-16 |
US20140348813A1 (en) | 2014-11-27 |
AU2008275025A1 (en) | 2009-01-15 |
IL202917A0 (en) | 2011-08-01 |
EP2170373A2 (en) | 2010-04-07 |
IL202917A (en) | 2015-08-31 |
WO2009009669A3 (en) | 2009-04-16 |
CO6290699A2 (es) | 2011-06-20 |
NZ582626A (en) | 2012-10-26 |
EP2170373B1 (en) | 2014-07-02 |
AU2008275025B2 (en) | 2014-06-05 |
ES2510551T3 (es) | 2014-10-21 |
US8637009B2 (en) | 2014-01-28 |
US9526786B2 (en) | 2016-12-27 |
WO2009009669A2 (en) | 2009-01-15 |
CN101903038A (zh) | 2010-12-01 |
HK1143309A1 (en) | 2011-04-15 |
US20170106056A1 (en) | 2017-04-20 |
AU2008275025C1 (en) | 2016-01-28 |
DK2170373T3 (da) | 2014-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010000410A (es) | Termoestabilizacion de proteinas. | |
WO2008057459A3 (en) | Antagonists of pcsk9 | |
WO2008057457A3 (en) | Antagonists of pcsk9 | |
WO2008057458A3 (en) | Antagonists of pcsk9 | |
WO2008133647A3 (en) | Antagonists of pcsk9 | |
UA101155C2 (ru) | Модифицированный полипептид фактора vii (fvii) и его применение | |
TNSN07076A1 (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
IN2012DN03824A (es) | ||
TW200745047A (en) | Heterocyclic compounds | |
MX2009002816A (es) | Proteinas de fusion de albumina. | |
SG165387A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
MY142589A (en) | Benzimidazole derivatives : preparation and pharmaceutical applications | |
BRPI0711767B8 (pt) | composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante | |
WO2008070672A3 (en) | Compositions and methods to treat cancer with cupredoxins and cpg rich dna | |
UA92348C2 (en) | 17b-HSD1 AND STS INHIBITORS | |
UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
WO2009038689A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
IN2012DN03368A (es) | ||
WO2009118722A3 (en) | Methods and compositions for oral administration of proteins | |
WO2008118148A3 (en) | Adiponectin for the treatment and diagnosis of albuminuria | |
WO2011002834A3 (en) | Compositions and methods for diagnosis and treatment of type 1 diabetes | |
BRPI0512503A (pt) | composição que compreende ácido lático e lactoferrina | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
MY157947A (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |